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Summary
Malaria is caused by obligate intracellular para-
sites, of which Plasmodium falciparum is the
most lethal species. In humans, P. falciparum
merozoites (invasive forms of the parasite) employ
a host of parasite proteins to rapidly invade eryth-
rocytes. One of these is the P. falciparum apical
membrane antigen 1 (PfAMA1) which forms a
complex with rhoptry neck proteins at the tight
junction. Here, we have placed the Pfama1 gene
under conditional control using dimerizable
Cre recombinase (DiCre) in P. falciparum. DiCre-
mediated excision of the loxP-flanked Pfama1 gene
results in approximately 80% decreased expres-
sion of the protein within one intraerythrocytic
growth cycle. This reduces growth by 40%, due to
decreased invasion efficiency characterized by a
post-invasion defect in sealing of the parasit-
ophorous vacuole. These results show that
PfAMA1 is an essential protein for merozoite inva-
sion in P. falciparum and either directly or indi-
rectly plays a role in resealing of the red blood cell
at the posterior end of the invasion event.
Introduction
Malaria, which is caused by Plasmodium parasites,
remains a major public health problem in large parts of
sub-Saharan Africa, tropical and subtropical regions of
Asia and the Americas. Plasmodium falciparum is the
most lethal species that infect humans (Snow et al.,
2005), although Plasmodium vivax is gaining importance
as a major cause of malaria mortality and morbidity
outside Africa (Guerra et al., 2010). Plasmodium para-
sites passage between the mosquito vector and human
host to complete their multi-stage development, adopting
multiple invasive ‘zoite’ forms throughout the process. In
humans, sporozoites are injected into the skin by female
Anopheles mosquitoes infected with malaria and they
rapidly invade hepatocytes to initiate the liver stage infec-
tion. These intracellular parasites develop into exoeryth-
rocytic merozoites that are released into the bloodstream
where they invade circulating erythrocytes. As obligate
intracellular parasites, merozoites mature within erythro-
cytes and develop cyclically through ring, trophozoite
and schizont stages inside a compartment termed the
parasitophorous vacuole. At the final stage of deve-
lopment, the parasite undergoes asexual division
(schizogony) to produce 16–32 daughter merozoites that
are released upon egress to invade new erythrocytes.
Invasion of erythrocytes by merozoites is a complex
and multistep process (reviewed in Cowman and Crabb,
2006). At egress an infected erythrocyte bursts releasing
merozoites that can attach to uninfected erythrocytes. The
low potassium level in the bloodstream triggers intracel-
lular calcium release activating sequential release of
micronemes and rhoptries, which are apical secretory
organelles that secrete proteins involved in the invasion
process (Singh et al., 2010). Once attached to an eryth-
rocyte, the merozoite reorientates its apical end to the
erythrocyte surface and an interface forms between the
two cells; a tight junction composed of parasite proteins
around the periphery of the merozoite apex on the cross-
sectional plane of invasion. Active invasion ensues as the
merozoite slides through the tight junction, which moves
from anterior to posterior end of the parasite cell. As the
merozoite penetrates the erythrocyte, proteins and lipids
are released from apical organelles into a pocket formed
primarily from the invaginating erythrocyte membrane
(Suss-Toby et al., 1996; Gruring et al., 2011; Riglar et al.,
2011). After the merozoite has completely entered
the erythrocyte, the membrane is closed forming the
parasitophorous vacuole and re-sealing the erythrocyte
membrane. As this takes place, the erythrocyte
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undergoes 5–10 min of echinocytosis (transient spike-
like extrusions of the erythrocyte membrane possibly
caused by dehydration) before the infected erythrocyte
reverts to its normal shape (Gilson and Crabb, 2009). By
this time, the merozoite has differentiated into an amoe-
boid ring-stage parasite (Gruring et al., 2011; Riglar et al.,
2011).
Apical membrane antigen 1 is one of a number of
proteins released from the parasite micronemes, and it
is a type I integral membrane protein synthesized in seg-
menting schizonts as an 83 kDa precursor protein.
When AMA1 is secreted onto the merozoite surface prior
to schizont rupture the prodomain is cleaved leaving a
66 kDa membrane-bound species (Crewther et al., 1990;
Narum and Thomas, 1994; Howell et al., 2001). AMA1
homologues exist in most apicomplexan parasites
including all Plasmodium species sequenced to date,
Toxoplasma gondii and Babesia divergens (Donahue
et al., 2000; Montero et al., 2009). The ectodomains of
AMA1 in Plasmodium share a similar tertiary structure
suggesting a conserved role (Bai et al., 2005). Paradoxi-
cally, AMA1 is also a highly polymorphic protein with
variation of approximately 10% of the amino acids
(Chesne-Seck et al., 2005). These sequence poly-
morphisms contribute to antibody escape and are there-
fore a major hurdle to generating an effective AMA1
vaccine (Healer et al., 2004). Nonetheless, AMA1 is a
leading blood stage vaccine candidate with evidence
showing some protection against clinical malaria in early
field trials (Thera et al., 2011).
Despite its importance for merozoite invasion, the bio-
logical function of PfAMA1 remained largely unknown
until recently. Early genetic studies in T. gondii suggest a
role for AMA1 in invasion of host cells. Viable TgAMA1
knockout mutants could not be obtained (Hehl et al.,
2000) and conditional knockout mutants of TgAMA1 were
severely impaired in host cell invasion (Mital et al., 2005).
The gene encoding PfAMA1 could not be disrupted in
asexual blood stages of P. falciparum and other species of
Plasmodium suggesting it was essential (Triglia et al.,
2000; Giovannini et al., 2011; Bargieri et al., 2013).
Perhaps the most highly studied aspect of AMA1 is for-
mation of the tight junction, a feature that was initially
observed as an electron-dense region at the point of
contact between an invading merozoite and the erythro-
cyte (Aikawa et al., 1978). The tight junction is thought to
serve as an anchor that together with the parasite
actomyosin motor provides the traction needed for
merozoites to pull itself into the erythrocyte (Tyler and
Boothroyd, 2011; Bargieri et al., 2012). The interaction
between PfAMA1 and another parasite protein called
rhoptry neck protein 2 (RON2) is essential for tight junc-
tion formation, which commits the merozoite for invasion
(Srinivasan et al., 2011b). RON2 is part of a larger RON
complex that also contains RON4 and RON5 (Alexander
et al., 2005; Collins et al., 2009; Riglar et al., 2011). The
RON complex appears to be released from the merozo-
ite’s rhoptry organelles prior to penetration and embeds in
the erythrocyte surface where it serves as an attachment
point for AMA1 (Lamarque et al., 2011).
Several lines of evidence support this AMA1–RON2
model of the tight junction. The AMA1–RON2 interaction
can be disrupted with small peptides such as RON2L,
which competes with native RON2 protein and leads to
inhibition of merozoite invasion (Srinivasan et al., 2011b).
AMA1-binding monoclonal antibodies inhibit merozoite
invasion by blocking the AMA1–RON2 interaction. Addi-
tionally, the peptide R1 (Harris et al., 2005) mimics the
structure of the AMA1-binding region of RON2 and as a
result blocks merozoite invasion and formation of the tight
junction (Vulliez-Le Normand et al., 2012).
However, experiments using AMA1 knockout and
knockdown mutants in P. berghei merozoites and
T. gondii tachyzoites have suggested that AMA1 plays no
role in tight junction formation but rather is important, but
not essential, for host cell attachment (Giovannini et al.,
2011; Bargieri et al., 2013). Additionally, these investiga-
tors showed that AMA1 is not required for merozoite rep-
lication in the erythrocyte and that the reduced
multiplication rate they observed of approximately 35%
reflects a defect in merozoite entry into the host cell
(Bargieri et al., 2013).
A dimerizable Cre recombinase (DiCre) technology
(Jullien et al., 2003) has been adapted for P. falciparum
and the related apicomplexan parasite T. gondii to
provide a rapid and efficient method for gene deletion
and conditional expression (Andenmatten et al., 2013;
Collins et al., 2013). Using DiCre technology we have
constructed a P. falciparum parasite in which expression
of the PfAMA1 protein is under conditional control result-
ing in knockdown of protein expression by approximately
80% in a single intraerytrocytic growth cycle. This results
in inhibition of merozoite invasion and provides evidence
that PfAMA1 is required for successful invasion into
erythrocytes.
Results
Conditional regulation of PfAMA1
The gene encoding PfAMA1 is refractory to genetic abla-
tion via conventional knockout strategies (Triglia et al.,
2000) and consequently we constructed a P. falciparum
line in which it was placed under conditional regulation. To
do this we simultaneously disrupted the endogenous
Pfama1 gene, in the W2mef line by single recombination,
with the plasmid pAMA1-loxP allowing complementation
with a transfected gene (encodes the antigenically distinct
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3D7 allele) flanked with loxP sites (Fig. 1). The resulting
W2mef/AMA1-loxP parasites were cloned by limiting dilu-
tion and the clones derived had two copies of the plasmid
inserted into the Pfama1 gene resulting in two functional
copies of the 3D7 allele (Figs 1 and 2A, Fig. S1).
In the second step we transfected the plasmid pDiCre,
which encodes the two conditionally dimerizable halves
of Cre recombinase, into W2mef/AMA1-loxP to derive
W2mef/AMA1-loxP/DiCre (Fig. 1). Normally, the DiCre
enzyme is inactive hence unable to recombine the loxP
sites and excise Pfama1. Cre recombinase is activated in
the presence of rapamycin as association of the two inac-
tive Cre fragments would occur via FK506-binding protein
(FKBP12) and FKBP12-rapamycin-binding (FRB) domain
of FRAP (FKBP12-rapamycin-associated protein) (Jullien
et al., 2003). Southern blot analysis of W2mef/AMA1-
loxP/DiCre parasites confirmed that the pDiCre plasmid
was present (Fig. 2B) and that endogenous Pfama1 gene
had been disrupted as expected (Fig. 2A). Two W2mef/
AMA1-loxP/DiCre clones were generated (referred to as
2F9 and B4) and used for subsequent analyses. Both 2F9
and B4 transgenic parasites exhibited normal growth rate
suggesting there was no deleterious effect of DiCre
expression in the absence of rapamycin (data not shown).
Fig. 1. Schematic for the sequential generation of W2mef/AMA1-loxP and W2mef/AMA1-loxP/DiCre parasites. In the first transfection, the
gene for Pfama1 in W2mef was genetically disrupted and complemented with a codon-altered 3D7 Pfama1 gene using the pAMA1-loxP
plasmid. The main features of pAMA1-loxP are a homologous target sequence for recombination followed by a W2mef promoter sequence
and a ‘floxed’ 3D7 Pfama1 gene. A hdhfr selectable drug cassette, which confers resistance to the antifolate WR99210, was used to select for
transfectants. Homologous integration of two tandemly arranged pAMA1-loxP plasmids into the W2mef AMA1 locus resulted in a duplication of
the 3D7 Pfama1 gene. The architecture of the modified locus is shown along with AflIII and NdeI restriction sites used for Southern blot
analysis. Sizes of the digested DNA fragments are shown in kilobase (kb). W2mef/AMA1-loxP parasites were cloned by limiting dilution. In the
second transfection, DiCre was introduced into a W2mef/AMA1-loxP clone using the pDiCre plasmid. The expression casette of pDiCre is
shown in the boxed insert (top right). The N- and C-terminus fragments of Cre recombinase are driven by the bi-directional P. berghei EF1α
promoter and hsp86 promoter respectively with both Cre fusions placed in a head-to-tail orientation. Transcription termination is modulated by
3′ UTR sequences of P. berghei dihydrofolate reductase-thymidylate synthase (DT 3′) and P. falciparum calmodulin (CAM 3′) genes. In the
DiCre system, Cre recombinase is fused to an F2 linker and either the FKBP12 or FRB sequence to induce dimerization in the presence of
rapamycin. We have included a Gal4 nuclear localization signal to target the DiCre fusion proteins to the nucleus once expressed and a bsd
resistance marker, which confers resistance to blasticidin. The predicted modification of the Pfama1 locus following DiCre-mediated Pfama1
excision is shown along with the restriction digest sizes.
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W2mef/AMA1-loxP and W2mef/AMA1-loxP/DiCre
parasites express a functional heterologous 3D7
AMA1 protein
Previously, we have generated transgenic P. falciparum
expressing heterologous Pfama1 alleles that differ in sus-
ceptibility to invasion inhibitory antibodies (Healer et al.,
2004). We made use of this strategy to disrupt the endog-
enous Pfama1 gene in W2mef while simultaneously
complementing loss-of-function with the antigenically
distinct 3D7 Pfama1 allele (Fig. 1). Complementation was
confirmed by immunoblot analysis of late-stage schizont
stages using a monoclonal antibody specific for the 3D7
PfAMA1 ectodomain and a PfAMA1 rabbit polyclonal anti-
body. Anti-3D7 AMA1 recognized the full-length and pro-
cessed forms of AMA1 (AMA183 and AMA166) in W2mef/
AMA1-loxP, 2F9 and B4 lines but not in W2mef parental
lines (Fig. 2C). In contrast, the polyclonal PfAMA1 anti-
body detected the protein in transgenic and parental lines
showing that W2mef/AMA1-loxP and W2mef/AMA1-loxP/
DiCre parasites indeed expressed the 3D7 AMA1 allele
(Fig. 2D).
Fig. 2. W2mef/AMA1-loxP and W2mef/AMA1-loxP/DiCre parasites are complemented with the 3D7 AMA1 protein.
A. Southern blot indicates that two copies of pAMA1-loxP have integrated into the W2mef Pfama1 locus leading to a duplication of the
heterologous 3D7 Pfama1 gene. The 4 and 3 kb AflIII fragments indicate the first and second copy of the full-length integrated plasmid (see
Fig. 1). Both 4 and 3 kb signals have equal intensity on the Southern blot, indicating that copy numbers are identical (i.e. 1:1 ratio). The
1.45 kb signal signifies the 3′ end of the modified locus where the second plasmid re-joins the endogenous, disrupted W2mef Pfama1 gene.
This signal is a single copy fragment hence it is used as DNA loading control for each track.
B. Southern blotting using XhoI restriction enzyme confirms the presence of the 9.3 kb full-length pDiCre plasmid in W2mef/AMA1-loxP/DiCre
parasites.
C. Immunoblot analysis of late-schizont extracts probed with the specific anti-3D7 AMA1 mAb 3A2 showing the two most abundant forms of
AMA1: the 83 kilodalton (kDa) precursor, AMA183 and the 66 kDa processed form, AMA166. The result shows that complementation with 3D7
AMA1 protein has occurred in W2mef/AMA1-loxP and W2mef/AMA1-loxP/DiCre clonal lines (2F9 and B4).
D. A polyclonal PfAMA1 antibody detected PfAMA1 signals from all tracks including parental W2mef confirming the result of the previous
immunoblot.
E. Parental and transgenic parasites were grown in media +/− R1 peptide. R1 peptide binds specifically to 3D7 PfAMA1 but not W2mef
PfAMA1. Complementation of W2mef/AMA1-loxP/DiCre parasites with a functional 3D7 PfAMA1 protein is evident as R1 peptide significantly
inhibited growth of 3D7, 2F9 and B4 parasites but not W2mef (n = 2 experiments with each done in triplicate). Error bars indicate standard
deviation (SD).
Conditional expression of PfAMA1 645
© 2014 The Authors. Cellular Microbiology published by John Wiley & Sons Ltd, Cellular Microbiology, 16, 642–656
To show that the 3D7 allele of PfAMA1 expressed in
the transgenic lines was functional we tested the ability
of the 20-residue peptide, R1, to inhibit merozoite inva-
sion into erythrocytes (Harris et al., 2005). The R1
peptide is strain-specific as it recognizes 3D7 AMA1 but
has a low affinity for W2mef AMA1. We carried out a
flow cytometry (FACS)-based growth assay by incubat-
ing 3D7, W2mef, 2F9 and B4 parasites with R1 peptide.
In the presence of R1, 3D7 parasite growth was inhib-
ited by approximately 80% while W2mef parasites were
not affected (Fig. 2E). In contrast, the growth of 2F9 and
B4 that expressed the 3D7 PfAMA1 was inhibited by
90–95% in the presence of R1 consistent with these
transgenic parasites expressing functional 3D7 AMA1
protein (Fig. 2E).
DiCre-mediated excision of the PfAMA1 gene
To determine the efficiency of DiCre-mediated excision
of the inserted Pfama1 genes, we first determined the
off-target effect of rapamycin on parasite growth (Fig.
S2A–C). Accordingly, we used rapamycin at 0.1 or
0.2 μM in subsequent experiments as W2mef and
W2mef/AMA1-loxP parasites grew normally at these
concentrations. Next, B4 and 2F9 parasites were syn-
chronized and incubated with either 0.1% DMSO or
0.1 μM rapamycin for 48, 96, 144 or 192 h. Genomic
DNA was extracted from parasites and analysed by
Southern blot to determine the level of DiCre-mediated
excision of Pfama1. A single-copy 3.7 kb band corre-
sponding to the 3′ end of the plasmid pAMA1-loxP
crossover was used as loading control (Figs 1 and 3A).
Rapamycin-induced excision of Pfama1 was demon-
strated by a shift from a band of 9.3 kb to 7.4 kb. The
percentage of excision varied from 70% to 92% as
quantified by densitometry in both B4 and 2F9 parasites
after 48 h with rapamycin (Fig. 3B and C). In each of the
subsequent time points, there was excision of Pfama1 to
the same extent of approximately 80% in both B4 and
2F9 parasites. The lack of an additive effect in terms of
the excision rate was unexpected since continuous
expression of DiCre should result in all of the Pfama1
genes being deleted. This was most likely because
expression of DiCre activity was not sufficient to excise
all Pfama1 copies within a single intraerythrocytic growth
cycle and approximately 20% expressed sufficient
protein to invade and survive.
Therefore we determined when DiCre activity could be
detected within one intraerythrocytic growth cycle by
Southern blot analysis. Excision of Pfama1 was first
detected at 30 h post incubation with rapamycin (Fig. 3D
and E). This was consistent with the EF1α bi-directional
promoter not being active during ring-stage of the parasite
life cycle (Fig. 1).
Excision of Pfama1 results in decreased
PfAMA1 expression
The amount of Pfama1 gene excision in the B4 and 2F9
populations was between 70–92% and we next deter-
mined the corresponding level of PfAMA1 protein expres-
sion when Cre recombinase activity was induced by
rapamycin. Schizont-stage parasites were analysed by
immunoblot using α-3D7 AMA1 antibody. There was
approximately 81% knockdown of AMA1 protein levels
across the four time points when compared with untreated
parasites (Fig. 4A–C). Expression of other invasion pro-
teins such as PfRh4, RON4 and EBA175 was unaffected
(Fig. 4D). This level of PfAMA1 protein knockdown corre-
lated with the level of Pfama1 gene excision mediated by
DiCre.
We next determined the level of PfAMA1 protein
expression using immunomicroscopy of untreated and
rapamycin-treated late stage schizonts. Parasites were
treated with rapamycin or DMSO for 48 h. This revealed a
gradient of PfAMA1 signal intensities ranging from high
levels to no detectable PfAMA1 for both conditions
(Fig. 4E). Parasites not treated with rapamycin also dis-
played some variation in PfAMA1 signal intensity depend-
ent upon the maturity of the schizonts (data not shown). To
impartially determine if rapamycin treatment resulted in
reduced PfAMA1 expression, the average pixel intensity
within a 70 pixel diameter region encompassing the
schizonts was measured. Only parasites positive for the
schizont-stage marker merozoite surface protein 1 (MSP1)
were counted because the timing of MSP1 protein expres-
sion is activated just before that of PfAMA1 (PlasmoDB,
http://plasmodb.org/plasmo). A histogram of the pixel
intensities confirmed that rapamycin treatment resulted in
less than half as many strongly staining AMA1-positive
parasites (+ rapamycin: 21 parasites; − rapamycin: 56
parasites) and more medium to weakly staining parasites
(+ rapamycin: 103 parasites; − rapamycin: 68 parasites)
(Fig. 4F). Of 124 schizonts observed, 83% were medium to
weakly staining AMA1-positive parasites in the rapamycin
treatment group compared with 55% in non-treated group.
The shift towards decreased PfAMA1 staining following
rapamycin treatment suggests deletion of Pfama1 was
directly contributing to reduction of PfAMA1. Microscopy of
schizonts with reduced PfAMA1 showed that all of the
merozoite microneme organelles within any particular
parasite cell were evenly stained indicating that the extent
of PfAMA1 knockdown was uniform between daughter
merozoites (Fig. 4E).
AMA1 knockdown leads to growth inhibition of
W2mef/AMA1-loxP/DiCre parasites
To determine if knockdown of PfAMA1 induced by DiCre
expression affected parasite growth and invasion, we
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measured the ability of W2mef/AMA1-loxP/DiCre cloned
parasite lines (2F9 and B4) to multiply in the presence of
rapamycin. Both 2F9 and B4 parasites showed a reduc-
tion in growth in a dose-dependent manner to a maximum
reduction of 40% over 72 h (Fig. 5A and B). We monitored
growth of rapamycin-treated W2mef/AMA1-loxP/DiCre
parasites through intraerythrocytic development and it
was found to be the same as non-rapamycin treated para-
sites supporting the idea that loss of PfAMA1 function was
affecting merozoite invasion (Fig. S3A). Furthermore,
parasite growth was monitored for extended periods
under rapamycin treatment. Rapamycin treatment had no
effect on W2mef/AMA1-loxP parasites, which lack DiCre
expression (Fig. 5C). In contrast, rapamycin-treated
W2mef/AMA1-loxP/DiCre parasites had greatly reduced
growth relative to untreated parasites (Fig. 5D and E).
These results showed that PfAMA1 was required for
normal growth of P. falciparum.
PfAMA1 is required for invasion of erythrocytes
by merozoites
We showed that PfAMA1 function in P. falciparum was
required for growth. To determine if this was due to an
essential role in invasion, purified merozoites of 2F9 and
B4 parasites were tested for their ability to invade eryth-
rocytes (Boyle et al., 2010). PfAMA1 protein knockdown
in the purified merozoites was confirmed by immunoblot
analysis that showed they expressed 60–80% less protein
following rapamycin treatment (data not shown). In four
Fig. 3. Efficient DiCre-mediated deletion of Pfama1 within one cycle of intraerythrocytic growth.
A. Representative Southern blots showing efficient DiCre-mediated excision of Pfama1 in clones B4 (top) and 2F9 (bottom) over four time
points each corresponding to an intraerythrocytic growth cycle. Highly synchronized ring-stage parasites were split into eight dishes. Half were
treated with 0.1 μM rapamycin (Rap) while the remaining dishes were treated with 0.1% DMSO as the vehicle control. Genomic DNA was
extracted for every treatment pair (Rap and DMSO) after 48, 96, 144 and 192 h when parasites were at the late-schizont stage. Southern
blotting of genomic DNA digested with NdeI detected three fragments in each track. An intact Pfama1 gene is represented by the
‘non-excised’ 9.3 kb fragment while deletion of Pfama1 gene is represented by the ‘excised’ 7.4 kb fragment. An additional 3.7 kb fragment
corresponds to the single-copy 3′ end of the pAMA1-loxP integration event and acts as a measure for DNA loading in each track. At each time
point, rapamycin treatment resulted in a higher proportion of ‘excised’ fragments compared with DMSO treatment, which showed almost
non-existential background DNA recombination (n = 2).
B. Densitometric quantification reveals Pfama1 excision rate ranges from 70–92% at each time point for B4 parasites. This was determined by
the ratio of the intensity of the ‘excised’ fragment to total intensity (‘excised’ and ‘non-excised’ fragments) in each track, normalized against
DNA loading (n = 2). Error bars indicate SD.
C. Similar analysis on 2F9 parasites results in equally efficient excision of Pfama1 (n = 2). Error bars indicate SD.
D. A Southern blot time-course on 2F9 parasites reveals that the ‘excised’ fragment was first detected at 30 h after addition of rapamycin.
DiCre-mediated excision of Pfama1 occurs during mid-to-late trophozoite stage.
E. Densitometric analysis of the Southern blot time-course indicates that a significant increase in Pfama1 deletion occurred between 15 and
30 h post rapamycin treatment.
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independent experiments for cloned lines 2F9 and B4,
rapamycin-mediated PfAMA1 knockdown resulted in
merozoite invasion between 43–85% of untreated control
(Fig. 5F). On average, merozoites invaded 37% less
effectively following rapamycin treatment for 48 h
(Fig. 5G) and this was in agreement with the growth inhi-
bition rate determined previously. Therefore PfAMA1 is
required for invasion of P. falciparum merozoites into
erythrocytes.
Real time imaging of rapamycin-treated
W2mef/AMA1-loxP/DiCre merozoites shows a
reduced ability to invade
Rapamycin-induced Pfama1 deletion resulted in a signifi-
cant reduction of merozoite invasion and we used real
time imaging to investigate the mechanistic defect. Live
W2mef/AMA1-loxP/DiCre parasites were imaged under
normal growth conditions following treatment with or
Fig. 4. Rapamycin strongly and specifically depletes PfAMA1 expression in late stage parasites.
A. Representative immunoblots show significantly decreased PfAMA1 expression following rapamycin treatment in B4 (top two panels) and
2F9 (bottom two panels) parasites over four time points. A monoclonal antibody specific for 3D7 AMA1 was used, which detected both the
unprocessed 83 kDa and processed 66 kDa PfAMA1. Anti-HSP70 was used as loading control.
B and C. By using densitometry quantification, PfAMA1 knockdown was estimated at an average of 81% for both parasite lines and in each of
the four time points (n = 2). Error bars indicate SD.
D. Immunoblot analysis indicates that expression of other rhoptry and micronemal proteins such as PfRh4, PfRON4 and PfEBA175 were not
reduced by rapamycin treatment.
E. Schizonts of rapamycin-treated parasites were dual labelled with anti-MSP1 (red) and anti-PfAMA1 (green) to show reduction in PfAMA1
expression. Schizonts displaying a gradient of high (arrow, top row), medium (bottom row) and low (arrowhead, top row) levels of PfAMA1
expression were observed. Scale bar is 5 μm.
F. Histogram of pixel brightness of PfAMA1 antibody-labelled parasites, categorized into three groups: strong, medium and weak/none.
Average pixel intensity for PfAMA1 was measured within a 70 pixel diameter surrounding the parasite and only MSP1-positive schizont stages
were selected.
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without rapamycin. Late-stage schizonts were imaged by
time-lapse microscopy for periods of 15–30 min. Follow-
ing schizont rupture, untreated W2mef/AMA1-loxP para-
sites merozoites behaved similarly to wild type merozoites
in that those that contacted erythrocytes deformed their
target cells for several seconds before penetration
(Fig. 6A) (Gilson and Crabb, 2009). Invasion itself lasted
approximately 10 s after which the erythrocyte underwent
echinocytosis 30–60 s later. Echinocytosis appears to be
caused by dehydration of the host cell (Tiffert et al., 2005)
and took an average of 376 s for recovery. During the
recovery process the merozoite could be observed trans-
forming into an amoeboid ring stage parasite (Gruring
et al., 2011; Riglar et al., 2011). Of 38 attempted invasions
observed for untreated merozoites 35 appeared success-
ful and 3 failed (Fig. 6D). In one of the failed invasions
the merozoite deformed the erythrocyte, triggered its
echinocytosis but failed to penetrate and remained
attached to the outside of the erythrocyte. In the other two
failed invasions the merozoites penetrated, triggered
echinocytosis but then reversed out of the invasion site
back onto the outside of the erythrocyte.
Following rapamycin treatment and knockdown of
PfAMA1 expression the proportion of merozoites failing to
productively invade and transform into a ring stage para-
site increased to approximately 40% (Fig. 6D). The
merozoites that failed to invade fell into two groups: first,
those that failed to penetrate, caused echinocytosis and
Fig. 5. PfAMA1 knockdown leads to
substantial growth inhibition due to decreased
merozoite invasion.
A and B. FACS-based growth assays show a
dose-dependent growth inhibition of 2F9 and
B4 parasites in the presence of rapamycin. At
0.1 μM rapamycin (non-inhibitory to wild type
growth), DiCre-mediated knockdown of
PfAMA1 resulted in 40% growth inhibition
(n = 3; triplicate experiments). Error bars
indicate SD.
C. Rapamycin does not affect
W2mef/AMA1-loxP parasite growth as both
DMSO- and rapamycin-treated parasites
expanded normally. Arrows denote splitting of
parasites (n = 2; triplicate experiments). A
representative experiment is shown. Error
bars indicate SD.
D and E. B4 and 2F9 parasites do not expand
normally over the course of a week upon
rapamycin-mediated PfAMA1 knockdown.
DMSO-treated parasites grew normally and
parasitemia were recorded up to four days
(n = 2 in triplicate). A representative
experiment is shown and similar results were
obtained for 2F9 parasites. Error bars indicate
SD.
F. Rapamycin-mediated PfAMA1 knockdown
results in reduced merozoite invasion of
erythrocytes. Invasion assays were performed
using purified merozoites incubated with
either 0.1 μM rapamycin or 0.1% DMSO v/v.
In four independent experiments,
rapamycin-treated 2F9 and B4 merozoites
invaded at 43–85% of DMSO-treated
merozoites.
G. On average, rapamycin treatment leads to
37% invasion inhibition in both 2F9 and B4
merozoites (n = 4; triplicate experiments).
Error bars indicate SD.
Conditional expression of PfAMA1 649
© 2014 The Authors. Cellular Microbiology published by John Wiley & Sons Ltd, Cellular Microbiology, 16, 642–656
remained attached (Fig. 6B) and second, those that pen-
etrated, triggered echinocytosis but failed to produce a
ring (Fig. 6C). In the latter group some merozoites exited
after penetration whilst others remained internal. In many
of the failed invasions the target erythrocyte remained an
echinocyte for a greatly extended period compared with
successful invasions suggesting a failure to reseal the
erythrocyte surface following penetration or attempted
penetration (Fig. 6E). In the case of the successful inva-
sions they generally had an echinocytosis period less
than 500 s (Fig. 6E). About 60% of the failed invasion
events for rapamycin-treated merozoites were character-
ized by echinocytosis periods more than 500 s consistent
with the idea that they had a defect in resealing the
invaded erythrocyte (Fig. 6E).
Discussion
AMA1 is one of the most intensely studied apicomplexan
ligands and much data has strongly implied an obligatory
role for this protein in the invasion of Plasmodium
merozoites into host erythrocytes. Notably, despite efforts
by numerous groups using different systems, it has not
proven possible to permanently delete the gene encoding
AMA1 in a range of Plasmodium species (Triglia et al.,
2000; Bargieri et al., 2013). While gene disruption has
proved impossible, studies using transgenic complemen-
tation approaches and inhibition of endogenous PfAMA1
using the R1 peptide have been successful (Healer et al.,
2004; Drew et al., 2012). These have provided a system
to test the function of PfAMA1 by inserting specific muta-
tions and through this added additional evidence that this
protein is required for merozoite invasion (Leykauf et al.,
2010). Together, the data reported in this study shows that
blood-stage growth is substantially impeded, probably
prevented altogether, in the absence of AMA1.
Mechanistically, it is known that AMA1 binds to another
parasite-encoded protein RON2 that is part of a parasite
complex injected into the host cell membrane at the pre-
invasion stage thereby functioning as an erythrocyte-
surface receptor (Besteiro et al., 2009; Cao et al., 2009;
Richard et al., 2010; Lamarque et al., 2011; Tonkin et al.,
2011; Tyler and Boothroyd, 2011). Indeed, during invasion
by P. falciparum merozoites PfAMA1 can be observed
forming a ring around the surface that moves with the tight
junction together with the RON complex consistent with it
Fig. 6. Rapamycin induction of DiCre results
in increased merozoites that cannot invade
erythrocytes.
A. Selected still images from a video
sequence showing an untreated merozoite
(arrow) successfully invading an erythrocyte
(Type I invasion). Time is shown in minutes
and seconds.
B. Rapamycin-treated merozoite (arrow) that
deforms but cannot invade its target
erythrocyte. The merozoite triggers
echinocytosis and remains attached to its
target erythrocyte (arrowheads) (Type II
invasion).
C. Rapamycin-treated merozoite (arrow) that
penetrates but fails to reseal its target
erythrocyte and does not develop into a
ring-stage parasite (Type III invasion).
D. The ratio of successful invasion (Type I)
versus unsuccessful invasion (Type II and III)
decreases in the presence of rapamycin
(P = 0.0052, Fisher’s exact test).
E. Rapamycin treatment results in a greater
percentage of failed invasion events. About
60% of the failed invasion events were due to
prolonged echinocytosis (EC) periods of
> 500 s (s). Note that the total number of
events (n) for +/− Rap is not the same in D
and E because the echinocytosis period could
not be ascertained for every invasion event.
650 A. Yap et al.
© 2014 The Authors. Cellular Microbiology published by John Wiley & Sons Ltd, Cellular Microbiology, 16, 642–656
binding directly to the RON complex and playing an
essential role in this process (Riglar et al., 2011). Using
different agents (antibodies and peptides) that block
the AMA1–RON2 interaction, much data has been gener-
ated in both Plasmodium merozoites and Toxoplasma
tachyzoites that suggests this interaction is absolutely
required for the establishment of the tight junction and
hence is essential for invasion (Hehl et al., 2000; Harris
et al., 2005; Richard et al., 2010; Lamarque et al., 2011;
Riglar et al., 2011; Srinivasan et al., 2011b). These data
are of course consistent with the inability to disrupt the
Plasmodium ama1 gene under circumstances that require
parasite maintenance in blood-stage culture.
Given the data described above, it was surprising that
deletion of the ama1 gene, using the conditional FLP/FRT
system in the rodent malaria parasite P. berghei, sug-
gested that AMA1 was not essential for tight-junction for-
mation or indeed for invasion (Bargieri et al., 2013).
Hence, uncertainty remains about the function of AMA1,
especially its role in the invasion of erythrocytes by Plas-
modium merozoites. In this paper, we sought to further
address the issue employing a different conditional
system and using in vitro cultured P. falciparum parasites.
We placed Pfama1 under conditional control in
P. falciparum merozoites using DiCre and an allelic
replacement strategy that allows excision of the functional
gene and concordantly decreased PfAMA1 expression in
the parasite population.
The imperfect nature of the genetic deletion event using
this system (∼ 80%), and the fact that the timing of dele-
tion is post-DNA replication (because the recombinase is
under the control of a trophozoite-stage promoter) means
that many of the schizonts will include a mixture of
merozoites that are genetically null and wild type for the
Pfama1 gene. In such circumstances we predicted the
PfAMA1 protein that is synthesized in these schizonts
should get distributed evenly to all the merozoites as
microneme biogenesis precedes parasite segmentation.
Indeed, our IFA data were consistent with the even AMA1
staining in each merozoites within schizonts that ranged
in brightness from very dull to bright. Hence, although the
genetic deletion is around 80%, the merozoites in the
rapamycin population have a range of AMA1 levels from
none, very low and close to normal (see Fig. 7).
Our PfAMA1-deficient merozoite population was unable
to invade erythrocytes as effectively as wild type para-
sites. Real time imaging of merozoite invasion has shown
that the ‘non-invaders’ can adhere to the erythrocyte
and cause characteristic deformations that precede acti-
vation of invasion. This is similar to the invasion pheno-
type observed following treatment with the R1 peptide
(Leykauf et al., 2010). Occupation of AMA1’s RON2
binding pocket by the R1 peptide prevents tight junction
formation but not echinocytosis, an event that is probably
triggered by rhoptry release occurring independently of
tight junction formation by permeabilizing the erythrocyte
Fig. 7. Model showing the role of AMA1 during merozoite invasion into erythrocytes. AMA1 is implicated in the initial stages of merozoite
invasion, including rhoptry secretion into erythrocytes, tight junction formation (Riglar et al., 2011) and possibly apical reorientation (Mitchell
et al., 2004) although this has recently been refuted (Srinivasan et al., 2011a). The tight junction serves as an anchor for the
myosin-dependent penetration of the merozoite (Gonzalez et al., 2009). The penetration step coincides with the formation of the
parasitophorous vacuole (PV) made up of rhoptry contents and a 5–10 min period of echinocytosis. Once the merozoite has completed its
entry, the PV pinches off the erythrocyte membrane, the erythrocyte re-seals and reverts back to its normal shape (Gilson and Crabb, 2009).
Expression of AMA1 is in excess in wild type parasites and as the level of AMA1 reduces, less efficient re-sealing of the erythrocyte
membrane occurs. This is shown by prolonged echinocytosis in which there is sufficient AMA1 to form a penetrative tight junction but not a
re-sealing tight junction. Further reduction of AMA1 leads to the inability to form tight junction and merozoite remains attached but do not
penetrate the erythrocyte.
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surface (Gilson and Crabb, 2009). Due to the phenotypic
similarity to R1 treatment it suggests that the rapamycin-
treated merozoites that failed to penetrate the host cell
probably have none or very small amounts of PfAMA1
expression (Fig. 7). Conversely, the rapamycin-treated
merozoites that penetrate their target erythrocytes prob-
ably have enough PfAMA1 to form a tight junction.
However, the merozoites that failed to seal the erythrocyte
behind them, and which in some cases exit via the inva-
sion pocket, probably lack sufficient PfAMA1 to enable the
tight junction to operate efficiently to pinch off the
parasitophorous vacuole and reseal the erythrocyte
plasma membrane (Fig. 7).
Interestingly, half of the rapamycin-treated merozoites
that successfully invaded have greatly extended
echinocytosis periods consistent with these parasites
having a less efficient tight junction. This implies that
PfAMA1 is in excess in normal parasites and that as its
level is reduced less efficient resealing occurs. Once the
PfAMA1 levels are reduced below a threshold a penetra-
tive tight junction can still be formed but its organization is
insufficient for resealing of the erythrocyte. Further reduc-
tion in PfAMA1 leads to no tight junction formation and
therefore no penetration.
As mentioned above, in a separate study by Bargieri
et al. conditional ama1 gene knockout mutants have been
obtained in P. berghei and T. gondii using a conditional
FLP/FRT system (Bargieri et al., 2013). While orthologues
and/or paralogues of AMA1 have been identified that may
function in its absence in Plasmodium sporozoites (e.g.
MAEBL) or T. gondii tachyzoites (Poukchanski et al.,
2013) there are no obvious candidates expressed in Plas-
modium merozoites that may complement AMA1 function
at this stage in the life cycle. Since these merozoites could
still invade despite not having any detectable AMA1 these
authors concluded that AMA1 was not essential for tight
junction formation or invasion (Bargieri et al., 2013), in
contrast to our data in this paper. However, another pos-
sible interpretation of their data is that these P. berghei
merozoites may possess small amounts of AMA1 protein;
due to incomplete gene excision in a given hepatic
schizont. Hence, with respect to Plasmodium merozoite
invasion of erythrocytes, it is possible that the results of
our study and that of Bargieri et al. are consistent
(Bargieri et al., 2013).
In conclusion, our data adds direct functional evidence
to an already very strong existing case that AMA1 is
essential for Plasmodium merozoite invasion and that it
operates by promoting tight-junction formation and func-
tioning. Moreover, intermediate levels of AMA1 expres-
sion in some of our merozoite mutants may have revealed
another role for AMA1 in the re-sealing of the tight-
junction following invasion. The latter clearly requires
more investigation.
Experimental procedures
Cloning of DNA constructs
Table S1 contains a list of all primers used in this study. pAMA1-
loxP was generated by modifying pCC1AMA1TP.1, an interme-
diate construct from a previous study (Drew et al., 2012).
pCC1AMA1TP.1 already contained the W2mef Pfama1 target
sequence and W2mef Pfama1 promoter. A full-length, codon-
optimized 3D7 Pfama1 sequence flanked by a pair of loxP sites
arranged as direct repeats was synthesized by Life Technologies
(USA). The 3D7 Pfama1 synthetic fragment was subsequently
cloned in pCC1AMA1TP.1 using KpnI and PstI to produce the
final construct, pAMA1-loxP. The DiCre components (boxed
insert in Fig. 1) were synthesized by Life Technologies (USA). A
nuclear localization signal (NLS) comprising the first 74 residues
of yeast Gal4 (Wittayacom et al., 2010) was included in the
N-terminal region of each component. In component 1 (C1), NLS
is followed by FKBP12, the F2 spacer and residues 19–59 of Cre
recombinase (Jullien et al., 2003). C1 is flanked by XhoI/PstI
restriction sites. Component 2 (C2) is composed of NLS, FRB, F2
spacer and residues 60–343 of Cre recombinase. C2 is flanked
by XmaI/SpeI restriction sites. The vector to express the DiCre
components was made based on pEF-Luc-GFP-DD29 (de
Azevedo et al., 2012). The selectable marker hDHFR was
replaced with blasticidin S-deaminase (BSD), which was
retrieved from pCC4 (Maier et al., 2008), then digested with
BamHI/HindIII and cloned in pEF-Luc-GFP-DD29 generating
pEF-Luc-GFP-DD29-BSD. P. berghei hDHFR 3′ UTR (DT 3′) was
PCR amplified from pCC1 (Maier et al., 2008) with primers
F-PbDT3-Pst and R-PbDT3-Mlu (Table S1), digested with PstI/
MluI and cloned in pEF-Luc-GFP-DD29-BSD, generating pEF-
Luc-DT3. C1 was cloned in XhoI/PstI sites of pEF-Luc-DT3,
generating pEF-C1-DT3. Heat shock protein 86 promoter
(HSP86 5′) was PCR amplified from pCC1 (Maier et al., 2008)
with primers F-HSP86-Mlu and R-HSP86-Xma, digested with
MluI/XmaI and cloned in pEF-C1-DT3, generating pEF-C1-DT3-
HSP. C2 was digested with XmaI/SpeI and cloned in pEF-C1-
DT3-HSP, generating the final construct pDiCre (Fig. 1).
Parasite cultures and transfections
Asexual blood stage cultures of P. falciparum 3D7 and W2mef
clones were maintained in human O+ erythrocytes using standard
conditions (Maier et al., 2008). The use of human erythrocytes for
parasite culturing was approved by the Walter and Eliza Hall
Human Research Ethics Committee (ethics number 86/17) and
an Australian Red Cross Blood Service Agreement (11-09VIC-
01). Transfection of W2mef parasites was as described (Crabb
et al., 2004). Briefly, synchronized ring-stage parasites at 5–8%
parasitemia were electroporated with 100 μg of plasmid. Stable
transformants of W2mef/AMA1-loxP were selected on the
antifolate drug, WR99210 (2.5 nM). Transfection of W2mef/
AMA1-loxP parasites with pDiCre was performed using the
Nucleofector® Technology (Lonza) (Janse et al., 2006). Mature
schizonts were isolated from a synchronized culture using 60%
Percoll solution (GE Healthcare). Purified schizonts were
transfected by electroporation with 50 μg of pDiCre using Amaxa
Nucleofactor® device (Lonza), Basic Parasite Nucleofactor® Kit 1
(Lonza) and program U33. W2mef/AMA1-loxP/DiCre parasites
were selected using blasticidin (2.5 μg ml−1, Invitrogen) and cul-
tured in a shaking incubator to improve parasite growth post
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transfection (Allen and Kirk, 2010). Two W2mef/AMA1-loxP/
DiCre clones, 2F9 and B4, were isolated by limiting dilution and
used for subsequent analyses.
Induction of DNA recombination
Rapamycin was obtained from LC Laboratories (USA) and
solubilized in DMSO at 2.73 mM. To induce dimerization of DiCre,
0.1 or 0.2 μM rapamycin was added to W2mef/AMA1-loxP/DiCre
clones with a final concentration of 0.1% DMSO in all cases.
DNA analysis by Southern blot
Parasite genomic DNA was isolated using standard phenol/
chloroform extraction methods (Sambrook et al., 1989). Two
digoxigenin (DIG)-labelled probes were synthesized using PCR
DIG Probe Synthesis Kit (Roche). The W2mef Pfama1 targeting
sequence probe was amplified with primers mo493 and mo492
using pAMA1-loxP plasmid as template (Table S1). As for the bsd
probe, pDiCe plasmid was used as the PCR template along with
primers aw317 and aw318 (Table S1). For Southern blots
genomic DNA was digested to completion with AflIII (for pAMA1-
loxP integration analysis), NdeI (for Pfama1 excision analysis) or
XhoI (to verify the presence of pDiCre), then separated on a 0.8%
agarose gel and transferred to Hybond N + nylon membrane (GE
Healthcare). Detection was performed using the DIG Easy Hyb
kit (Roche) according to manufacturer’s protocol. Quantification
of the Southern blot signals was performed using Quantity One
1-D Analysis Software (Bio-Rad).
Immunoblot
Synchronous mature schizonts were harvested and suspended
in 0.15% saponin. Saponin pellet was solubilized in SDS sample
buffer and separated by SDS-PAGE. Immunoblots of AMA1 were
analysed using monoclonal antibody (mAb) 3A2, which specifi-
cally recognizes 3D7 AMA1. Other antibodies used in this study
include a rabbit polyclonal AMA1 antibody R190, polyclonal anti-
body against EBA-175 R1179, PfRh4 mAb 2E8 and mAb against
PfRON4. Anti-HSP70 polyclonal antibody was used as loading
control.
Intracellular parasite growth assay
Parasite growth assays were performed as previously described
(Wilson et al., 2010). Synchronized ring-stage parasites were
plated in triplicates (50 μl) at 1% parasitemia and 1% haemato-
crit. Rapamycin or DMSO was added with a 1 in 10 dilution to
assess growth inhibition over one cycle of intraerythrocytic
growth. Parasites were cultured for 72 h through to the next cycle
when most parasites progressed to mature trophozoites. Para-
sites were stained with 10 μg ml−1 ethidium bromide (EtBr; Bio-
Rad) for an hour and parasitemia was assessed by flow
cytometry. The R1 peptide growth assay used the same protocol
and R1 peptide was added at 100 μg ml−1.
Merozoite invasion inhibition assay
Merozoites were purified based on an established method (Boyle
et al., 2010). Highly synchronized ring-stage parasite of clones
2F9 and B4 (typical culture volume of 200 ml each, > 5%
parasitemia and 2–3% haematocrit) were split and grown in
0.1 μM rapamycin or 0.1% DMSO v/v until they were late
schizonts. Schizonts were isolated from uninfected erythrocytes
with a MAC magnet separation column (Macs; Miltenyi Biotech).
Purified schizonts were incubated with 10 μM of the cysteine
protease inhibitor E64 to prevent schizont ruptures. After 5–6 h of
incubation, schizont pellets were passaged through a 1.2 μm
syringe filter (Acrodisc; 32 mm; Pall). Filtrate containing purified
merozoites was plated out in triplicates (10 μl each well, topped
up with media to total 50 μl) with the addition of 0.5% uninfected
erythrocytes. Plates were agitated for 10 min. In the next cycle
when parasites progressed to become mature trophozoite-stage,
parasitemia was assessed by flow cytometry as described earlier.
Remaining purified merozoites not used in this assay were
pelleted and solubilized in SDS sample buffer for Western blot
analysis. Also, purified merozoites were retrospectively quantified
using CountBright® absolute counting beads (Life Technologies)
to ensure that the number of purified merozoites added at the
start of the invasion assays was the same between rapamycin
treament and DMSO treatment.
An alternative method was used for measuring invasion inhi-
bition following multiple cycles of growth in the presence of
rapamycin. 250 μl of sorbitol-synchronized, ring-stage 2F9 clone
were cultured in a 96-well microtitre plate at 1% hematocrit.
Samples were plated in triplicate and treated with either DMSO or
rapamycin. 50 μl of samples from each well were removed, fixed
with 0.25% glutaraldehyde in 1× phosphate buffered saline (PBS)
and then incubated with 100 μl of SYBR Green I (Invitrogen) for
15 min. Cells were finally resuspended in PBS for flow cytometry.
Samples were collected on day 0 to day 7 with each sample
about 24 h apart. Initial gating was carried out with wild type 3D7
parasites and by comparing to Giemsa smears, this method
accurately distinguishes ring-stage from late-stage parasites.
Microscopy
Air-dried smears of infected erythrocytes were fixed in ice-cold
methanol for 5 min and then blocked for 1 h in PBS with 1%
casein. Parasites were probed with rabbit polyclonal IgG to
MSP1–19 (60 μg ml−1) and mouse monoclonal IgG to PfAMA1
(2H4, 100 μg ml−1) in blocking buffer for 1 h. After briefly washing
twice in PBS with 0.05% Tween 20 and once in PBS, the para-
sites were probed in goat anti-rabbit Alexa 568 and anti-mouse
Alexa 488 (both at 1 in 2000, Invitrogen) for 1 h. After washing as
above, the parasites were mounted in Vectashield with DAPI
(Vector). Images were taken on a Zeiss AxioObserver with a 100×
oil lens and manipulated in ImageJ. For measuring PfAMA1
intensity all images were captured with the same exposure time
and adjusted to the same minimum and maximum threshold
settings of 160 and 2012 respectively. A 70-pixel diameter circle
was drawn around each schizont and the minimum, average and
maximum pixel intensities were acquired in ImageJ and manipu-
lated in Microsoft Excel and Prism (Graphpad Software).
Real-time imaging
Late stage W2mef/AMA1-loxP/DiCre (2F9 and B4) schizonts
(2 ml) at 0.16% hematocrit were settled onto a 35 mm Fluorodish
(World Precision Instruments) and imaged on an inverted Zeiss
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AxioObserver microscope in brightfield. The sample chamber
was heated to 37°C and supplied with a humidified 1% O2, 5%
CO2 and 94% N2 atmosphere.
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Fig. S1. Southern blot analysis of W2mef/AMA1-loxP parasite
clones. Of the eight clones isolated, seven has two tandem
pAMA1-loxP plasmids integrated into the Pfama1 gene locus
resulting in two copies of the 3D7 Pfama1 gene inserted. Clone
#3 was selected for subsequent transfection of pDiCre.
Fig. S2. Identifying optimal rapamycin concentration for efficient
DiCre activation with no off-target toxicity effects.
A. Rapamycin dose response curve was fitted using
W2mef parasites. Rapamycin was added at ring-stage and
incubated over one or two cycles of parasite replication.
Parasite growth was determined by FACS and normalized
against untreated W2mef parasites. IC50 of rapamycin was
determined to be 2.7 μM, close to previously published results
(n = 2; triplicate experiments) (Bell et al., 1994). Error bars indi-
cate SD.
B. W2mef parasites incubated with varying amounts of
rapamycin indicate that wild type parasite growth is not affected
up to 300 nM of rapamycin. Beyond that, there is a dose depend-
ent inhibition of growth. DMSO is inhibitory above 0.1% v/v (n = 3;
triplicate experiments). Error bars represent SD.
C. Similar growth assays were performed on W2mef/AMA1-loxP
parasites to confirm that at 300 nM or below, rapamycin does not
induce observable growth inhibitory effect in the absence of
DiCre expression.
Fig. S3. DiCre-mediated PfAMA1 knockdown has no adverse
effects on intraerythrocytic development but lead to invasion
inhibition.
A. Synchronized W2mef/AMA1-loxP/DiCre parasites were incu-
bated with either 0.1% DMSO v/v or 0.1 μM rapamycin at early-
to-mid ring stage. At 10, 20 and 35 h after the addition of
rapamycin or DMSO, Giemsa smears were made. Parasitemia
was measured and the proportion of ring, trophozoite or schizont
stages is presented as a fraction of a pie chart. At all time points,
the proportion of ring, trophozoite and schizont stages is compa-
rable between the two treatments.
B. Closer inspection of parasite growth and reinvasion using
SYBR Green I. DMSO-treated parasites displayed normal growth
phenotype as the majority of the ring-stage parasites on day 0
progressed to late-stage parasites on day 1. On day 2, a majority
of the late-stage parasites reinvaded to form new ring-stage
parasites resulting in a doubling of total parasitemia. Total
parasitemia may be higher if samples were processed later as
not all of the late-stages have egressed and reinvaded. Parasites
were split roughly 1:2 (between days 2 and 3) and 1:3 (between
days 4 and 5) as denoted by the vertical dashed lines. A repre-
sentative sample of a triplicate experiment is shown.
C. Rapamycin-treated parasites displayed normal intraery-
throcytic growth but failed to invade normally. As expected, most
of the ringstage parasites on day 0 progressed to late-stages on
day 1 thereby confirming that rapamycin does not adversely
affect parasite growth. Between days 1 and 2, however, total
parasitemia had expanded from 2.7% to 3.7%, reflecting a
37% drop in invasion efficiency compared with DMSO-treated
parasites. Invasion efficiency of rapamycin-treated parasites in
comparison to DMSO-treated parasites varies in subsequent
reinvasion cycles with a drop of 46% between days 3 and 4 and
18% between days 5 and 6. Parasites were split roughly 1:2
(between days 2 and 3) and 1:3 (between days 4 and 5) to be
consistent with DMSO-treatment. A representative sample of a
triplicate experiment is shown.
D. Representative flow cytometry plots showing different cell
populations of ring-stage parasites, late-stage parasites and
uninfected erythrocytes. Each column corresponds to a repre-
sentative sample that was processed and stained with SYBR
Green I about 24 h apart from the adjacent time point.
Table S1. List of primers used in this study.
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